# US 2004/0072255 A1 · Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072255 A1
- Document ID: US20040072255A1
- Status: Published application
- Kind: A1
- Application number: 10/270,838
- Filed: 2002-10-11
- Published: 2004-04-15
- Earliest claimed: 2002-10-11
- Assignees: Queen's University at Kingston
- Inventors: Jennifer E. Van Eyk; Jeremy A. C. Simpson; Ninetta Buscemi; Michelle K. Quick
- Web page: https://patentgrep.com/patent/US20040072255A1

## CPC

- C12Q 1/485: {involving kinase}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Isolated phosphorylated troponin I proteins useful in diagnosing and monitoring the phosphorylation state of injured muscle tissue are provided. Also provided are compounds, kits and methods for assessing the phosphorylation state of these troponin I proteins and modulating the phosphorylation state of these troponin I proteins in a subject.

## Claims

### Claim 1

An isolated post-translationally modified myofilament protein comprising a troponin I protein phosphorylated at its C terminus or adjacent to its minimal inhibitory region.

### Claim 2 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is phosphorylated at its C terminus and adjacent to its minimal inhibitory region.

### Claim 3 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is fast skeletal troponin I phosphorylated at serine 117 or serine 168.

### Claim 4 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is fast skeletal troponin I phosphorylated at serine 117 and serine 168.

### Claim 5 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is human cardiac troponin I phosphorylated at serine 149 or serine 198.

### Claim 6 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is human cardiac troponin I phosphorylated at serine 149 and serine 198.

### Claim 7 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is rat cardiac troponin I phosphorylated at serine 150 or serine 199.

### Claim 8 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is rat cardiac troponin I phosphorylated at serine 150 and serine 199.

### Claim 9 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is slow skeletal troponin I phosphorylated at serine 118 or serine 168.

### Claim 10 (depends on 1)

The isolated post-translationally modified myofilament protein of claim 1 wherein the troponin I is slow skeletal troponin I phosphorylated at serine 118 and serine 168.

### Claim 11 (depends on 1)

A method of detecting native troponin I and phosphorylated troponin I in a sample comprising contacting the sample with a compound that binds to native troponin I and phosphorylated troponin I of claim 1.

### Claim 12 (depends on 11)

The method of claim 11 wherein the compound is an antibody mAb FI-32.

### Claim 13 (depends on 1)

A method for distinguishing native troponin I from a phosphorylated troponin I in a sample comprising contacting the sample with a compound which binds to native troponin I but not to a phosphorylated troponin I of claim 1.

### Claim 14 (depends on 13)

The method of claim 13 wherein the compound is an mAb 8I-7.

### Claim 15 (depends on 1)

A kit for distinguishing native troponin I from a phosphorylated troponin I comprising:
(a) a compound which binds to native troponin I and the phosphorylated troponin I of claim 1; and
(b) a compound which binds to native troponin I but not to the phosphorylated troponin I of claim 1.

### Claim 16 (depends on 15)

The kit of claim 15 wherein the compound of (a) is an antibody mAb FI-32.

### Claim 17 (depends on 15)

The kit of claim 15 wherein the compound of (b) is antibody mAb 8I-7.

### Claim 18 (depends on 1)

An antibody which selectively binds the isolated post-translationally modified myofilament protein of claim 1.

### Claim 19 (depends on 1)

An aptamer which selectively binds the isolated post-translationally modified myofilament protein of claim 1.

### Claim 20 (depends on 1)

A method of diagnosing or monitoring injury of skeletal and cardiac muscle in a subject comprising determining a phosphorylation state of the isolated post-translationally modified myofilament protein of claim 1 in a biological sample obtained from the subject.

### Claim 21 (depends on 1)

A method for assessing efficacy of a therapy for muscle damage in a subject comprising:
(a) determining a phosphorylation state of the isolated post-translationally modified myofilament protein of claim 1 in a first biological sample obtained from a subject;
(b) administering a therapy to the subject; and
(c) determining a phosphorylation state of the isolated post-translationally modified myofilament protein of claim 1 in a second biological sample obtained from the subject following administration of the therapy; and
(d) comparing the phosphorylation state determined in step (a) with the phosphorylation state determined in step (b) to identify changes in the phosphorylation state indicative of efficacy of the therapy.

### Claim 22 (depends on 1)

A method for assessing appropriateness of a level of training and/or enhancement performing drug in a subject comprising monitoring a phosphorylation state of the isolated post-translationally modified myofilament protein of claim 1 troponin I in these subjects during training or administration of the enhancement performing drug.

### Claim 23 (depends on 1)

A composition comprising an agent targeted to a phosphatase or kinase which alters a phosphorylation state of the isolated post-translationally modified myofilament protein of claim 1.

### Claim 24 (depends on 23)

The composition of claim 23 wherein the phosphatase is protein phosphatase I.

### Claim 25 (depends on 23)

The composition of claim 23 wherein the kinase is p21-activated kinase.

### Claim 26 (depends on 23)

A method for modulating a phosphorylation state of troponin I in a subject comprising administering to the subject a composition of claim 23.
